Neurotech International Ltd. · ASX:NTI
Neurotech International — Investor Presentation (November 2020)
15 slides from Neurotech International's investor presentation, Nov 16, 2020
Slide 1: Investor Presentation November 2020
For personal use only I N V E S TO R P R E S E N TATI O N November 2020 BRIDGING TO A BETTER LIFE • Neurotech International Limited (ASX: NTI)
Slide 2: Disclaimer
Disclaimer For personal use only IMPORTANT INFORMATION Purpose of presentation: This presentation (including this document, any related video or oral These events are, as at the date of this presentation, expected to take place, but there cannot be any presentation, any question and answer session a
Slide 3: Overview
Overview For personal use only $ Neurotech is focussed on Neurotech’s Mente device & Mente continues to gain Neurotech has acquired an the development & therapy is clinically proven to recognition as a therapeutic exclusive worldwide licence commercialisation of increase engagement & improve tool wi
Slide 4: The device
The device For personal use only 01 02 Proven Complementary Technology & Versatile Mente is world’s first home-based brain Enables clinics, doctors & training therapy that is clinically proven therapists to expand their to increase engagement & improve practice into the home with relaxation in autis
Slide 5: Increased recognition of Mente globally
Increased recognition of globally For personal use only CE Marking for the Mente device recently Mente therapy referral program adopted renewed, enabling continued marketing by Norcal Brain Center (USA) and & sales of the device in Europe Australasian Neurofeedback Institute (ANFI) Secured Brain The
Slide 6: Neurotech licences cannabis strains targeting autism
Neurotech licences cannabis strains targeting autism For personal use only • Neurotech has acquired an exclusive worldwide license to utilise proprietary cannabis strains from Dolce Cann Global • Potential for these strains in medicinal use to treat neurological disorders including autism, epilepsy
Slide 7: Significant potential for cannabis in neurological disorders
Significant potential for cannabis in neurological disorders For personal use only Phytocannabinoids are being analysed 120+ phytochemicals in cannabis plant – studies in studies around the world to indicate certain strains may provide relief from determine their influence over the neurological diso
Slide 8: Results from Neurotech's cannabinoid analysis
Results from Neurotech’s cannabinoid analysis For personal use only • Final results from Neurotech’s analysis of 80 cannabis samples from the Dolce Cann Global genetic portfolio return a variety of cannabinoids, including newly discovered phytocannabinoids CBDP and CBDB • All 80 samples contained va
Slide 9: Expected pathway of cannabis project
Expected pathway of cannabis project For personal use only 1. In vitro assay assessments 2. Product formulation and 3. Small scale human Neuronal or muscle cell line assessments final dose profiling (efficacy) clinical trials Analytical assessments & To be conducted in collaboration Commencing in ea
Slide 10: Preliminary Results from In vitro Studies
Preliminary Results from In vitro Studies For personal use only Key Findings Studies were designed to assess the In all studies the top DOLCE/NTI strains demonstrated superiority when compared to CBD alone. neuroprotective and • DOLCE/NTI strains demonstrated reduction in brain cell inflammation (up
Slide 11: Neurological Disorders Market Opportunity
Neurological Disorders Market Opportunity For personal use only Global market for neurological disorder treatment is estimated to be US$112b per year by 2027 growing at 5% p.a. The global medical The World Health Over 4 million registered Neurotech’s unique marijuana market was Organization estimate
Slide 12: Industry Peer Overview
Industry Peer Overview For personal use only Neurotech Zelira Cann India Globalisation Botanix Company International Therapeutics Global Capital Pharmaceuticals Ticker ASX: NTI ASX: ZLD ASX: CGB NYSE: IGC ASX: BOT Market ~$15m ~$86m ~$26m ~US$53m ~$102m Capitalisation Treatment of Pharmaceutical Dev
Slide 13: Highly Experienced Board
Highly Experienced Board For personal use only Brian Leedman Mark Davies Winton Willesee Chairman Non-Exec Non-Exec (Non-Exec) Director Director • More than 15 years’ experience in the • More than 20 years’ experience in • Experienced company director with biotechnology sector trading, investment ba
Slide 14: Corporate Overview
Corporate Overview For personal use only CAPITAL STRUCTURE 12-Month Share Price Performance 120 $0.035 Millions Share price $0.03 (as at 13 Nov 2020) 100 $0.030 $0.025 80 Shares on issue 500.6m $0.020 60 $0.015 Options 161.32m^ 40 $0.010 Cash at bank ~$2,000,000 20 $0.005 0 $0.000 Market capitalisat
Slide 15: Contact Details
For personal use only C O N TAC T D E TA I LS Brian Leedman Winton Willesee Chairman Non-Executive Director [email protected] [email protected] +61 412 281 780 +61 410 667 844 This presentation has been authorised for release by the Board of Neurotech International Limited. • Neur
Neurotech International — Investor Presentation (November 2020) on 6ix